Search

everythinglearnresearchcommunity

for

Search:↓

Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.

Metformin and thiazolidinediones are similarly effective for PCOS, but metformin is often preferred due to fewer side effects.

People with alopecia areata have more inflammation but similar heart risk as healthy people.

The bulletin provides guidelines for diagnosing and managing PCOS, suggesting weight loss, hormonal contraceptives, and diabetes screening, with clomiphene for infertility and various treatments for excess hair.

Mood stabilizers like lithium and anticonvulsants have side effects that can lead to patients stopping their medication, and managing these effects is important for treatment adherence.

Severe vertex pattern hair loss may indicate a higher risk for artery plaque buildup.

Young women with PCOS without additional risk factors may have normal heart function.

Young women with PCOS and no other heart risk factors have normal heart function.

High Lipid Accumulation Product levels are linked to more hirsutism in women with Polycystic Ovary Syndrome.

Women with hair loss have higher heart disease risk and unhealthy cholesterol levels.

Early-onset male hair loss may be linked to higher cardiovascular risk.

Hirsutism is excessive hair growth in women often caused by polycystic ovarian syndrome, and identifying the cause is important for managing associated health risks.

Higher hs-CRP levels in Indian adolescent women with PCOS are more related to BMI than PCOS itself.

Testosterone therapy can help with androgen deficiency in women but should be used with caution and monitoring due to potential risks.

Hormone therapy is essential for transgender individuals but requires careful management due to possible metabolic effects.

The 2003 consensus updated PCOS diagnosis criteria and linked PCOS to higher risks of diabetes and heart problems, recommending lifestyle changes to lower these risks.

The guideline suggests using specific criteria to diagnose PCOS, recommends various treatments for its symptoms, and advises screening for related health issues.

The document concludes that PCOS is a complex disorder caused by both genetic and environmental factors, affecting women's health in various ways, and requires personalized treatment.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

The guide recommends specific methods for diagnosing PCOS and various treatments for its symptoms, while considering the health impacts on adolescents.

Metformin helps with menstrual cycles and insulin levels in PCOS but is less effective for hair growth, diabetes prevention, and weight loss, and may improve fertility and reduce diabetes risk.

Women with the NIH type of PCOS have more obesity and higher risk of diabetes and heart disease than those with other types of PCOS.

The Endocrine Society advised against routine testosterone therapy for women, citing a need for more research on long-term safety and a clear definition of androgen deficiency.

Insulin resistance and obesity are key factors in the development and worsening of polycystic ovary syndrome, and lifestyle changes are important for managing it.

Hormone treatments for transgender individuals generally improve mental health and physical transition, with some health risks that require medical supervision.

High androgen levels in young women with PCOS are linked to higher blood pressure.

Testosterone therapy in transgender men has both desired effects like increased muscle mass and potential health risks such as higher cardiovascular risk.

Women with PCOS face higher risks of diabetes and heart disease, and these risks increase with obesity.

Early diagnosis and individualized treatment improve outcomes for Congenital Adrenal Hyperplasia.

Oral testosterone therapy raises heart risk more than other methods.